{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:58Z","timestamp":1786119358874,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/mol.0b013e3283325083","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T03:16:25Z","timestamp":1259032585000},"page":"467-476","source":"Crossref","is-referenced-by-count":24,"title":["What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?"],"prefix":"10.1097","volume":"20","author":[{"given":"Harold E","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210205","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 1","key":"R2-4-20210205","first-page":"S13","article-title":"Standards of medical care in diabetes: 2009.","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"R3-4-20210205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel.","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"R4-4-20210205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"R5-4-20210205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"R6-4-20210205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1520-037X.2003.03142.x","article-title":"Once-daily niacin extended release\/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin","volume":"6","author":"Bays","year":"2003","journal-title":"Prev Cardiol"},{"issue":"11A","key":"R7-4-20210205","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.amjcard.2007.09.080","article-title":"Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?","volume":"100","author":"Kamanna","year":"2007","journal-title":"Am J Cardiol"},{"key":"R8-4-20210205","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccl.2008.06.007","article-title":"Extended-release niacin\/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors","volume":"26","author":"Paolini","year":"2008","journal-title":"Cardiol Clin"},{"key":"R9-4-20210205","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14779072.2.4.485","article-title":"Extended-release niacin\/lovastatin: the first combination product for dyslipidemia","volume":"2","author":"Bays","year":"2004","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R10-4-20210205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R11-4-20210205","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R12-4-20210205","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol\u2013niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"R13-4-20210205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"R14-4-20210205","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA"},{"key":"R15-4-20210205","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"R16-4-20210205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2008.04.044","article-title":"Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells","volume":"202","author":"Ganji","year":"2009","journal-title":"Atherosclerosis"},{"key":"R17-4-20210205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1742-1241.2008.01934.x","article-title":"Does nicotinic acid (niacin) lower blood pressure?","volume":"63","author":"Bays","year":"2009","journal-title":"Int J Clin Pract"},{"key":"R18-4-20210205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clinthera.2009.01.010","article-title":"Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin\/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients","volume":"31","author":"Bays","year":"2009","journal-title":"Clin Ther"},{"issue":"6A","key":"R19-4-20210205","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"R20-4-20210205","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clinthera.2009.01.011","article-title":"Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview","volume":"31","author":"Kamal-Bahl","year":"2009","journal-title":"Clin Ther"},{"key":"R21-4-20210205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0163-7827(93)90017-Q","article-title":"Prostanoid receptors and their biological actions","volume":"32","author":"Negishi","year":"1993","journal-title":"Prog Lipid Res"},{"key":"R22-4-20210205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-006-0211-2","article-title":"The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers","volume":"63","author":"Van Hecken","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-4-20210205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"R25-4-20210205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270009332246","article-title":"Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms","volume":"49","author":"Dishy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R26-4-20210205","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.clpt.6100345","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist","volume":"83","author":"Lai","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"8A","key":"R27-4-20210205","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data: 2005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"R29-4-20210205","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R30-4-20210205","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2008.01739.x","article-title":"Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial","volume":"62","author":"Paolini","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R31-4-20210205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"R32-4-20210205","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"R33-4-20210205","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"issue":"10B","key":"R34-4-20210205","doi-asserted-by":"crossref","first-page":"30K","DOI":"10.1016\/S0002-9149(02)02971-5","article-title":"Existing and investigational combination drug therapy for high-density lipoprotein cholesterol","volume":"90","author":"Bays","year":"2002","journal-title":"Am J Cardiol"},{"key":"R36-4-20210205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","article-title":"Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice","volume":"99","author":"Kamal-Bahl","year":"2007","journal-title":"Am J Cardiol"},{"key":"R37-4-20210205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"R38-4-20210205","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"issue":"12A","key":"R39-4-20210205","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"R40-4-20210205","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"R41-4-20210205","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"R42-4-20210205","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"key":"R43-4-20210205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study","volume":"94","author":"Rubenfire","year":"2004","journal-title":"Am J Cardiol"},{"key":"R45-4-20210205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOL.0b013e3283325083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:43Z","timestamp":1786039423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041433-200912000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e3283325083","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}